UBC Acquires Evidinno, Forging an AI-Powered RWE Powerhouse

KING OF PRUSSIA, PA – January 06, 2026 – United BioSource LLC (UBC) has officially acquired Evidinno Outcomes Research Inc., a move that creates a formidable new force in the rapidly evolving biopharmaceutical services landscape. The acquisition combines UBC’s global scale in late-stage research with Evidinno’s specialized, AI-driven expertise in real-world evidence (RWE) and health economics and outcomes research (HEOR), signaling a significant strategic play in a market increasingly dependent on data to prove therapeutic value.

This transaction brings Vancouver-based Evidinno, a respected healthcare research consultancy, under the umbrella of UBC, a leader in evidence generation solutions. Evidinno will operate as a wholly owned subsidiary, integrating its advanced analytical capabilities into UBC's broader service offerings. The deal, for which Fairmount Partners acted as exclusive financial advisor to Evidinno, is poised to reshape how drug developers generate the proof needed for regulatory approval, market access, and commercial success.

A Strategic Play in a High-Growth Market

The acquisition arrives at a pivotal moment for the pharmaceutical industry. The global market for RWE solutions, valued at over $17 billion in 2024, is projected to surge to nearly $50 billion by 2032, propelled by a compound annual growth rate exceeding 13%. Similarly, the HEOR services market is expanding at a comparable pace, driven by a fundamental shift in healthcare towards value-based care.

Regulators like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are increasingly accepting RWE to support label expansions and post-market requirements. Simultaneously, payers and health technology assessment (HTA) bodies demand robust economic models and outcomes data to justify reimbursement for new, often costly, therapies. This dual pressure has made sophisticated HEOR and RWE capabilities not just advantageous, but essential for survival.

By acquiring Evidinno, UBC is making a decisive move to meet this demand head-on. The merger deepens its expertise in evidence synthesis, epidemiology, and advanced economic analysis, creating a comprehensive, end-to-end solution for biopharma clients. This allows UBC to better support clients across the entire product lifecycle, from late-stage clinical development through the long-term demonstration of a product's real-world safety, effectiveness, and value.

Fusing Global Scale with AI-Driven Expertise

The true power of this acquisition lies in the synergy between UBC’s established infrastructure and Evidinno’s cutting-edge technological approach. While UBC provides a global platform and deep relationships within the biopharma sector, Evidinno brings a highly specialized toolkit that leverages artificial intelligence to accelerate and enhance evidence generation.

Evidinno has earned a reputation for its 'AI-enabled, expert-led' methodologies. These include advanced literature review systems that use large language models to screen thousands of scientific articles in minutes, as well as capabilities for complex network meta-analyses and health economic modeling. This fusion of human expertise with AI-powered efficiency dramatically reduces the time and resources required to synthesize the vast amounts of data needed for regulatory and HTA submissions. As a result, biopharma sponsors can get critical answers on treatment effectiveness and value faster than ever before.

"Evidinno's scientific rigor and technology enabled‑ workflows deepen our ability to curate fit-for-purpose evidence and health economic and outcomes insights for our clients," said Aaron Berger, SVP Evidence Development Solutions at UBC. "Together, we will transform the evidence value chain and help sponsors answer important questions on the safety and effectiveness of treatments for patients."

This sentiment was echoed by Evidinno's leadership. "Joining UBC marks an important step in expanding the reach and influence of Evidinno's scientific and methodological expertise," stated Dr. Mir Sohail Fazeli, MD, PhD, Chief Executive Officer of Evidinno. He emphasized that the combination would position the new entity to "deliver robust, decision-ready evidence that supports sponsors and improves outcomes for patients world-wide."

Reshaping the Competitive Landscape

This acquisition is not happening in a vacuum. It is part of a broader trend of consolidation within the contract research organization (CRO) and healthcare consulting sectors. In recent years, the market has seen a flurry of mergers and partnerships as service providers race to build integrated ecosystems. Companies are striving to become one-stop-shops capable of handling every aspect of a drug's journey to market, from data linkage and analytics to regulatory consulting and market access strategy.

The UBC-Evidinno deal positions the combined company more competitively against industry giants like IQVIA, ICON, and Evidera (a part of Thermo Fisher Scientific), which have long offered comprehensive RWE and HEOR services. By integrating Evidinno's niche AI expertise, UBC not only broadens its service portfolio but also sharpens its technological edge, offering a differentiated value proposition in a crowded field.

This trend toward consolidation reflects the growing complexity of drug development. Biopharma companies, facing immense pressure to demonstrate value, increasingly prefer to partner with a single, strategic provider that can manage the intricate web of evidence requirements. The merger is a clear signal that scale, combined with specialized technological prowess, is becoming the new standard for success in the evidence generation market.

The Future of Evidence Generation for Biopharma

For UBC's current and future clients, the acquisition promises a more streamlined, powerful, and efficient pathway to demonstrating product value. The integrated offering means pharmaceutical and biotech firms can access a full spectrum of services—from modernized late-stage study design to AI-assisted evidence synthesis and sophisticated economic modeling—all under one roof.

This integration is designed to produce what the industry covets most: decision-ready evidence. This is data curated and analyzed with such rigor that it can confidently be presented to regulators to gain approval and to payers to secure favorable reimbursement and market access. By combining Evidinno's HTA- and regulatory-grade solutions with UBC's global reach, the company is better equipped to help clients navigate these critical hurdles.

The ultimate goal, as stated by both companies, is to ensure that safe and effective therapies are made available to the patients who need them. By modernizing the evidence development pathway, this acquisition aims to shorten timelines, strengthen value propositions, and ultimately improve patient outcomes on a global scale.